1. Home
  2. UTHR vs SGI Comparison

UTHR vs SGI Comparison

Compare UTHR & SGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • SGI
  • Stock Information
  • Founded
  • UTHR 1996
  • SGI 1846
  • Country
  • UTHR United States
  • SGI United States
  • Employees
  • UTHR N/A
  • SGI N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • SGI Home Furnishings
  • Sector
  • UTHR Health Care
  • SGI Consumer Discretionary
  • Exchange
  • UTHR Nasdaq
  • SGI Nasdaq
  • Market Cap
  • UTHR 14.4B
  • SGI 12.7B
  • IPO Year
  • UTHR 1999
  • SGI N/A
  • Fundamental
  • Price
  • UTHR $308.00
  • SGI $60.07
  • Analyst Decision
  • UTHR Buy
  • SGI Strong Buy
  • Analyst Count
  • UTHR 12
  • SGI 4
  • Target Price
  • UTHR $392.00
  • SGI $66.75
  • AVG Volume (30 Days)
  • UTHR 439.7K
  • SGI 2.8M
  • Earning Date
  • UTHR 04-30-2025
  • SGI 05-08-2025
  • Dividend Yield
  • UTHR N/A
  • SGI 0.25%
  • EPS Growth
  • UTHR 18.86
  • SGI N/A
  • EPS
  • UTHR 25.10
  • SGI 1.50
  • Revenue
  • UTHR $2,994,100,000.00
  • SGI $5,346,200,000.00
  • Revenue This Year
  • UTHR $11.45
  • SGI $57.44
  • Revenue Next Year
  • UTHR $6.11
  • SGI $6.99
  • P/E Ratio
  • UTHR $12.27
  • SGI $40.08
  • Revenue Growth
  • UTHR 19.84
  • SGI 8.96
  • 52 Week Low
  • UTHR $260.41
  • SGI $45.04
  • 52 Week High
  • UTHR $417.82
  • SGI $69.87
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 57.25
  • SGI N/A
  • Support Level
  • UTHR $290.02
  • SGI N/A
  • Resistance Level
  • UTHR $319.40
  • SGI N/A
  • Average True Range (ATR)
  • UTHR 10.02
  • SGI 0.00
  • MACD
  • UTHR 2.72
  • SGI 0.00
  • Stochastic Oscillator
  • UTHR 69.99
  • SGI 0.00

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About SGI Somnigroup International Inc. Common Stock

Somnigroup International Inc is a bedding company, dedicated to improving people's lives through better sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries worldwide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.

Share on Social Networks: